Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both dry powder and liquid inhalation formulations in collaboration with Lumen Bioscience, the University of Alabama at … [Read more...] about Gates Foundation awards $1.9 million grant to Aridis for development of inhaled mAbs
Business
Leyden Labs raises $140 million for development of intranasal vaccines
Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company's pipeline, which includes its PanFlu intranasal mAb vaccine against both influenza A and B. Leyden Labs previously announced a €40 million Series A financing in March 2021. In … [Read more...] about Leyden Labs raises $140 million for development of intranasal vaccines
Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene
According to Opiant Pharmaceuticals, the company's contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene nasal spray for the treatment of opioid overdose. In July 2021, Opiant announced positive results … [Read more...] about Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene
Aculys Pharma gets rights to Valtoco nasal spray in Japan, Australia, and other Asia-Pacific countries
Aculys Pharma has acquired development and commercialization rights to Neurelis's Valtoco diazepam nasal spray in Japan, Australia, and other Asia-Pacific countries, including New Zealand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, South Korea, Thailand and Vietnam. Aculys, which launched in 2021, describes itself as "a biopharmaceutical … [Read more...] about Aculys Pharma gets rights to Valtoco nasal spray in Japan, Australia, and other Asia-Pacific countries
Lotus gets rights to market Ryaltris nasal spray in Singapore, Hong Kong, and Vietnam
Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make an upfront payment as well as future payments based on regulatory and sales milestones. Glenmark … [Read more...] about Lotus gets rights to market Ryaltris nasal spray in Singapore, Hong Kong, and Vietnam
Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray
According to Pneumagen, the company has closed a £3.8 million funding round led by Thairm Bio and Scottish Enterprise, with proceeds intended to fund GMP manufacturing and Phase 2 development of its Neumifil carbohydrate binding module (mCBM) nasal spray for the prevention of respiratory viruses. Pneumagen initiated a Phase 1 study of Neumifil in November 2021 and … [Read more...] about Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray
CFF awards grant to Feldan Therapeutics for development of pulmonary delivery technology for CF
The Cystic Fibrosis Foundation has awarded funding to Feldan Therapeutics for development of the company's Feldan Shuttle technology for pulmonary delivery of drugs to treat cystic fibrosis. Neither the company nor the CFF disclosed the amount of the award, which was made under the CFF's Path to a Cure initiative. Social media posts from the CFF said that the purpose … [Read more...] about CFF awards grant to Feldan Therapeutics for development of pulmonary delivery technology for CF
Medlab Clinical gets grant from NSW government for intranasal RNA vaccine against COVID-19
Australian biotech Medlab Clinical said that it has received a grant from the New South Wales government for development of a proof-of-concept intranasal vaccine based on its NanoCelle "sub-micron delivery platform" technology. The company added that it will develop the vaccine in partnership with OINDP specialist Daniela Traini of the Woolcock Institute of Medical … [Read more...] about Medlab Clinical gets grant from NSW government for intranasal RNA vaccine against COVID-19
Poolbeg Pharma licenses intranasal antiviral from the University of Warwick
Open Orphan spin-out Poolbeg Pharma said that it has acquired an exclusive license for an intranasal RNA-based immunotherapy for the prevention and treatment of viral respiratory infections from the University of Warwick. According to the company, in vivo studies have demonstrated that the antiviral, which Poolbeg is calling POLB 002, has the potential to be effective … [Read more...] about Poolbeg Pharma licenses intranasal antiviral from the University of Warwick
Covis to distribute Seebri Breezhaler and Ultibro Breezhaler in Canada
Covis Pharma Canada announced that it has signed a 7-year promotion and distribution agreement with Novartis Pharmaceuticals Canada for exclusive rights to Seebri Breezhaler glycopyrronium DPI and Ultibro Breezhaler indacaterol / glycopyrronium for the treatment of COPD in Canada. In November 2021, Covis announced that it had acquired global rights to market … [Read more...] about Covis to distribute Seebri Breezhaler and Ultibro Breezhaler in Canada